Radiolabeled polymeric nanoconstructs loaded with docetaxel and curcumin for cancer combinatorial therapy and nuclear imaging

Cinzia Stigliano, Jaehong Key, Maricela Ramirez, Santosh Aryal, Paolo Decuzzi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Growing evidence suggests that multifaceted diseases as cancer can be effectively tackled by hitting simultaneously different biological targets and monitoring patient-specific responses. Combinatorial therapies, relying on the administration of two or more molecules with different cytotoxic mechanisms, are rapidly progressing in the clinic. Here, 100 nm spherical polymeric nanoconstructs (SPNs) are proposed for the combinatorial treatment of tumors by codelivering a potent antimitotic drug - docetaxel (DTXL) - and a broad spectrum anti-inflammatory molecule - curcumin (CURC). In vitro, SPNs loaded with DTXL and CURC induce a threefold decrease in IC50 as compared to DTXL-loaded SPNs. This synergic antitumor effect is also significant in mouse models of glioblastoma multiforme, where, after 22 d of treatment, the combinatorial approach leads to complete disease regression. At 90 d post-treatment initiation, mice injected with DTXL + CURC SPNs have a 100% survival, whereas only 50% of the DTXL SPN treated mice survive. SPNs are also labeled with radioactive 64Cu(DOTA) molecules to document, via PET imaging, the progressive tumor mass shrinkage. Sensitization of DTXL by CURC is associated with NF-κB downregulation and increased apoptosis. These theranostic nanoconstructs could be used for combinatorial treatment and assessment of therapeutic efficacy in other malignancies. Spherical polymeric nanoconstructs (SPNs) are multifunctional nanoparticles designed for combinatorial therapy and disease management. The platform presented here is used to codeliver docetaxel, a strong antitumor drug, with curcumin as sensitizing agent. SPNs are labeled with 64Cu for PET imaging to detect the delivery of SPNs and follow the therapy efficacy over time. This combinatorial approach is successful in glioblastoma xenograft mouse model.

Original languageEnglish
Pages (from-to)3371-3379
Number of pages9
JournalAdvanced Functional Materials
Volume25
Issue number22
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

docetaxel
Curcumin
mice
therapy
cancer
Imaging techniques
Molecules
Tumors
Patient monitoring
drugs
tumors
Cell death
molecules
sensitizing
apoptosis
shrinkage
Nanoparticles
regression analysis
delivery
platforms

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Materials Science(all)
  • Condensed Matter Physics

Cite this

Stigliano, Cinzia ; Key, Jaehong ; Ramirez, Maricela ; Aryal, Santosh ; Decuzzi, Paolo. / Radiolabeled polymeric nanoconstructs loaded with docetaxel and curcumin for cancer combinatorial therapy and nuclear imaging. In: Advanced Functional Materials. 2015 ; Vol. 25, No. 22. pp. 3371-3379.
@article{c41cd43c290f40aa9596fd42cf95769d,
title = "Radiolabeled polymeric nanoconstructs loaded with docetaxel and curcumin for cancer combinatorial therapy and nuclear imaging",
abstract = "Growing evidence suggests that multifaceted diseases as cancer can be effectively tackled by hitting simultaneously different biological targets and monitoring patient-specific responses. Combinatorial therapies, relying on the administration of two or more molecules with different cytotoxic mechanisms, are rapidly progressing in the clinic. Here, 100 nm spherical polymeric nanoconstructs (SPNs) are proposed for the combinatorial treatment of tumors by codelivering a potent antimitotic drug - docetaxel (DTXL) - and a broad spectrum anti-inflammatory molecule - curcumin (CURC). In vitro, SPNs loaded with DTXL and CURC induce a threefold decrease in IC50 as compared to DTXL-loaded SPNs. This synergic antitumor effect is also significant in mouse models of glioblastoma multiforme, where, after 22 d of treatment, the combinatorial approach leads to complete disease regression. At 90 d post-treatment initiation, mice injected with DTXL + CURC SPNs have a 100{\%} survival, whereas only 50{\%} of the DTXL SPN treated mice survive. SPNs are also labeled with radioactive 64Cu(DOTA) molecules to document, via PET imaging, the progressive tumor mass shrinkage. Sensitization of DTXL by CURC is associated with NF-κB downregulation and increased apoptosis. These theranostic nanoconstructs could be used for combinatorial treatment and assessment of therapeutic efficacy in other malignancies. Spherical polymeric nanoconstructs (SPNs) are multifunctional nanoparticles designed for combinatorial therapy and disease management. The platform presented here is used to codeliver docetaxel, a strong antitumor drug, with curcumin as sensitizing agent. SPNs are labeled with 64Cu for PET imaging to detect the delivery of SPNs and follow the therapy efficacy over time. This combinatorial approach is successful in glioblastoma xenograft mouse model.",
author = "Cinzia Stigliano and Jaehong Key and Maricela Ramirez and Santosh Aryal and Paolo Decuzzi",
year = "2015",
month = "6",
day = "1",
doi = "10.1002/adfm.201500627",
language = "English",
volume = "25",
pages = "3371--3379",
journal = "Advanced Functional Materials",
issn = "1616-301X",
publisher = "Wiley-VCH Verlag",
number = "22",

}

Radiolabeled polymeric nanoconstructs loaded with docetaxel and curcumin for cancer combinatorial therapy and nuclear imaging. / Stigliano, Cinzia; Key, Jaehong; Ramirez, Maricela; Aryal, Santosh; Decuzzi, Paolo.

In: Advanced Functional Materials, Vol. 25, No. 22, 01.06.2015, p. 3371-3379.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Radiolabeled polymeric nanoconstructs loaded with docetaxel and curcumin for cancer combinatorial therapy and nuclear imaging

AU - Stigliano, Cinzia

AU - Key, Jaehong

AU - Ramirez, Maricela

AU - Aryal, Santosh

AU - Decuzzi, Paolo

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Growing evidence suggests that multifaceted diseases as cancer can be effectively tackled by hitting simultaneously different biological targets and monitoring patient-specific responses. Combinatorial therapies, relying on the administration of two or more molecules with different cytotoxic mechanisms, are rapidly progressing in the clinic. Here, 100 nm spherical polymeric nanoconstructs (SPNs) are proposed for the combinatorial treatment of tumors by codelivering a potent antimitotic drug - docetaxel (DTXL) - and a broad spectrum anti-inflammatory molecule - curcumin (CURC). In vitro, SPNs loaded with DTXL and CURC induce a threefold decrease in IC50 as compared to DTXL-loaded SPNs. This synergic antitumor effect is also significant in mouse models of glioblastoma multiforme, where, after 22 d of treatment, the combinatorial approach leads to complete disease regression. At 90 d post-treatment initiation, mice injected with DTXL + CURC SPNs have a 100% survival, whereas only 50% of the DTXL SPN treated mice survive. SPNs are also labeled with radioactive 64Cu(DOTA) molecules to document, via PET imaging, the progressive tumor mass shrinkage. Sensitization of DTXL by CURC is associated with NF-κB downregulation and increased apoptosis. These theranostic nanoconstructs could be used for combinatorial treatment and assessment of therapeutic efficacy in other malignancies. Spherical polymeric nanoconstructs (SPNs) are multifunctional nanoparticles designed for combinatorial therapy and disease management. The platform presented here is used to codeliver docetaxel, a strong antitumor drug, with curcumin as sensitizing agent. SPNs are labeled with 64Cu for PET imaging to detect the delivery of SPNs and follow the therapy efficacy over time. This combinatorial approach is successful in glioblastoma xenograft mouse model.

AB - Growing evidence suggests that multifaceted diseases as cancer can be effectively tackled by hitting simultaneously different biological targets and monitoring patient-specific responses. Combinatorial therapies, relying on the administration of two or more molecules with different cytotoxic mechanisms, are rapidly progressing in the clinic. Here, 100 nm spherical polymeric nanoconstructs (SPNs) are proposed for the combinatorial treatment of tumors by codelivering a potent antimitotic drug - docetaxel (DTXL) - and a broad spectrum anti-inflammatory molecule - curcumin (CURC). In vitro, SPNs loaded with DTXL and CURC induce a threefold decrease in IC50 as compared to DTXL-loaded SPNs. This synergic antitumor effect is also significant in mouse models of glioblastoma multiforme, where, after 22 d of treatment, the combinatorial approach leads to complete disease regression. At 90 d post-treatment initiation, mice injected with DTXL + CURC SPNs have a 100% survival, whereas only 50% of the DTXL SPN treated mice survive. SPNs are also labeled with radioactive 64Cu(DOTA) molecules to document, via PET imaging, the progressive tumor mass shrinkage. Sensitization of DTXL by CURC is associated with NF-κB downregulation and increased apoptosis. These theranostic nanoconstructs could be used for combinatorial treatment and assessment of therapeutic efficacy in other malignancies. Spherical polymeric nanoconstructs (SPNs) are multifunctional nanoparticles designed for combinatorial therapy and disease management. The platform presented here is used to codeliver docetaxel, a strong antitumor drug, with curcumin as sensitizing agent. SPNs are labeled with 64Cu for PET imaging to detect the delivery of SPNs and follow the therapy efficacy over time. This combinatorial approach is successful in glioblastoma xenograft mouse model.

UR - http://www.scopus.com/inward/record.url?scp=85027952721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027952721&partnerID=8YFLogxK

U2 - 10.1002/adfm.201500627

DO - 10.1002/adfm.201500627

M3 - Article

AN - SCOPUS:85027952721

VL - 25

SP - 3371

EP - 3379

JO - Advanced Functional Materials

JF - Advanced Functional Materials

SN - 1616-301X

IS - 22

ER -